Former Theranos exec Ramesh Balwani convicted of fraud
SAN JOSE, Calif. — A jury on Thursday convicted former Theranos executive Ramesh “Sunny” Balwani…
Author: STAT
Listen: VC malaise, FDA confusion, & yet another Alzheimer’s debate
Is the era of the unicorn over? What’s gotten into the FDA? And will a…
Opinion: Community-level risk: an ‘uninformative’ guide for Covid-19 prevention
For the first time since the Centers for Disease Control and Prevention introduced its three-level…
Remote technology could nudge patients to join cancer clinical trials
You’re reading the web edition of STAT Health Tech, our guide to how tech is…
STAT+: Pharmalittle: Merck closes in on acquisition of Seagen; Intercept declares victory after re-analyzing NASH data
Good morning, everyone. Damian Garde here, filling in for Ed Silverman as the days of…
STAT+: With ‘do-over’ NASH results, Intercept will seek approval for first-ever treatment for fatty liver condition
Intercept Pharmaceuticals said Thursday that an extensive re-analysis of a large clinical trial involving its…
Opinion: Hospitals and for-profit PBMs are diverting billions in 340B savings from patients in need
America’s economically disadvantaged patients can point in two directions when talking about what is wrong…
Opinion: Are tax-exempt hospitals giving back their fair share to communities? It depends on what you count
Nonprofit hospitals in the U.S. are exempt from most taxes. To earn this status, they…
STAT+: In a high-profile misstep, the FDA backtracks on its ban on Juul
WASHINGTON — The FDA suddenly reversed course this week on its efforts to ban Juul…
Doctors are clamoring for more clarity on Paxlovid prescribing amid Covid-19 rebound concerns
Six months after regulators issued an emergency use authorization for Paxlovid, physicians say they still…
STAT+: Here’s what Democrats changed in their latest drug pricing bill
WASHINGTON — Senate Democrats have put final tweaks on their drug pricing proposal, as they…
STAT+: In the search for an ARPA-H director, the White House is zeroing in on DARPA veterans
WASHINGTON — The White House is zeroing in on former DARPA officials as candidates to…
From social media to pink billboards, it’s suddenly ‘hot’ to discuss gut diseases
LOS ANGELES — Near the corner of busy Santa Monica Boulevard and Corinth Avenue, underneath…
Common injections don’t help knee osteoarthritis more than placebo, large data review finds
A commonly used treatment for people with knee osteoarthritis is barely more effective than the…
STAT+: Under new ownership, IBM Watson Health’s core assets get a rebranding
The IBM Watson Health brand comes with baggage. But for its new owners, the core…
Opinion: The FDA owes parents an explanation about why it delayed authorizing Moderna’s Covid-19 vaccine for young kids
Until mid-June, 1 in 13 persons living in the United States — that’s all children…
STAT+: Pharmalittle: Some scientists want more Vertex CRISPR data; Biogen Alzheimer’s drug to get priority review
Good morning. Elizabeth Cooney here, sitting in for Ed Silverman again, wishing him sunny skies…
Opinion: The monkeypox vaccine underscores the value of U.S. investments in preparedness
After living through the Covid-19 epidemic, many people around the world reacted to the sudden…
Opinion: STAT+: Why health care organizations need to invest in workforce career advancement
In a tight health care labor market, health care companies must be creative in attracting…
The 41 best books and podcasts on health and science to check out this summer
With the arrival of summer comes a chance to relax, reflect, and escape the day…
Estimates of long Covid are startlingly high. Here’s how to understand them
Think about the adults you know: Does 1 out of every 5 have long Covid,…
STAT+: Beyond a CRISPR treatment’s encouraging results, some scientists see a need for more data on risk
What happens when you CRISPR people? Few questions generated more contentious discussion in biotech in…
In a boost for species conservation, freeze-dried mouse cells produce healthy pups
Two years after scientists at the Roslin Institute in Scotland delivered Dolly the sheep, the…
STAT+: FDA to convene second panel of outside experts to review Amylyx Pharma’s ALS treatment
Amylyx Pharmaceuticals said Tuesday that the Food and Drug Administration is bringing together a panel…
STAT+: Pharmalittle: Market downturn chills VC climate; drug distributors prevail in W. Va. opioids case
Good morning. Elizabeth Cooney here again, pinch-hitting for Ed Silverman. Although he sometimes makes his…
STAT+: Marijuana-induced high blunted by Anebulo Pharma pill, early study shows
Anebulo Pharmaceuticals said Tuesday that a single dose of its experimental pill blunted the effects…
Opinion: The accuracy of pulse oximeters shouldn’t depend on a person’s skin color
Covid-19 made pulse oximeters an even more important tool for measuring the amount of oxygen…
STAT+: The Q3 health tech tracker: 11 key industry events and debates to watch
It’s been a humbling first half of the year for health tech companies. Previously abundant…
STAT+: The biotech scorecard for the third quarter: 18 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third…
‘A scary time’: Fear of prosecution forces doctors to choose between protecting themselves or their patients
Last Wednesday, a patient walked into Julie Rhee’s fertility clinic in St. Louis with pelvic…
STAT+: ‘Really scared and frightened’: VC deals and valuations begin falling apart as biotech’s stock shock becomes one of the longest in history
The drug industry is experiencing one of the longest market downturns it has ever seen,…
STAT+: Can Biogen’s backup plan for Alzheimer’s succeed?
Everyone needs a backup plan, including one of the biggest biotech companies in town. So…
Opinion: THC ingestion by young kids highlights the need to tighten inadequate packaging regulations
Tetrahydrocannabinol (THC), the psychoactive ingredient in marijuana, is finding its way into the hands and…
Health tech companies are scrambling to close data privacy gaps after abortion ruling
In the wake of the Supreme Court decision to overturn Roe v. Wade, reproductive health…
STAT+: ‘A slippery slope’: Pfizer sells a contraceptive and donated to political groups that could come after the company
Generally speaking, a company would not want to contribute to a politician whose actions could…
STAT+: ‘A slippery slope’: Drugmakers that sell contraceptives donated to political groups that could come after them
Generally speaking, a company would not want to contribute to a politician whose actions could…
STAT+: Pharmalittle: Senate Dems vet a tweaked version of drug-pricing bill; biotechs double down on developing birth control products
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Not-so-happy midyear! Biotech CEOS, best and worst, and a hopeful sign of a turnaround
A few things on my mind: A very strange — and painful — year in…
Opinion: Improve CDC’s quarantine stations to prevent the next pandemic
In today’s interconnected world, people, packages, and animals can circumnavigate the globe in less than…
STAT+: After abortion ruling, biotechs developing contraceptives say their work is more important — and fraught — than ever
SAN DIEGO — From San Diego to New Jersey, biotechs developing new forms of birth…
STAT+: Medicare wants to stop publishing some hospital safety data next year
Ann MacDonald took painstaking effort to choose the very best surgeon for her mom’s colon…
STAT+: A Celldex treatment induces symptom relief in patients with chronic hives
An experimental drug from Celldex Therapeutics induced complete symptom relief in half of patients with…
Supreme Court’s decision on abortion sparks health tech’s Cambridge Analytica moment
In 2018, the tech industry found itself in a harsh spotlight amid a scandal involving…
STAT+: The near-term outlook for pharma industry earnings just got a little worse
The near-term earnings outlook for the pharmaceutical industry was revised downward by a major credit…
Listen: Medical privacy post-Roe, fixing clinical trials, & the next Covid vaccines
How do you stop a Covid surge? Why are clinical trials so white? And what…
Baking trust into tech, Cerebral’s prescribing, & the evolution of post-Roe privacy
You’re reading the web edition of STAT Health Tech, our guide to how tech is…
Democrats tweak their drug pricing plan in last-ditch effort to pass reforms
WASHINGTON — Senate Democrats are vetting a new, tweaked version of a drug pricing package as…
STAT+: New analysis of Amarin’s Vascepa resurrects big questions about effectiveness
A new analysis of Vascepa, a medicine derived from fish oil and used to prevent…
The unlikely crusader who’s winning the fight to lower hospital prices
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
FDA recommends vaccine makers update Covid-19 shots to target Omicron
The Food and Drug Administration is advising vaccine makers to reformulate their Covid-19 shots to…